title: High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy.
authors.forename: A
authors.initials: A
authors.lastname: Banerjee
authors.forename: K
authors.initials: K
authors.lastname: Wynne
authors.forename: T
authors.initials: T
authors.lastname: Tan
authors.forename: E C
authors.initials: EC
authors.lastname: Hatfield
authors.forename: N M
authors.initials: NM
authors.lastname: Martin
authors.forename: C
authors.initials: C
authors.lastname: Williamson
authors.forename: K
authors.initials: K
authors.lastname: Meeran
mesh_terms: D000328:Adult; D000077465:Cabergoline; D004873:Ergolines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000150:complications / Q000188:drug therapy; D007231:Infant, Newborn; D010911:Pituitary Neoplasms / Q000150:complications* / Q000188:drug therapy*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D011388:Prolactin / Q000037:antagonists & inhibitors; D015175:Prolactinoma / Q000150:complications* / Q000188:drug therapy*
chemical_list: D004873:Ergolines; D011388:Prolactin; D000077465:Cabergoline